Nebula Genomics and EMD Serono collaborate

Blockchain Genomics Firm, Nebula Genomics announced a collaboration with EMD Serono, the biopharmaceutical business of Merck on 11 June.

Nebula Genomics commenced by informing that they were starting a pilot project, the goal of which was to help EMD Serono to enhance its research efforts. It would achieve this by supporting its scientists as they develop new medicines. Nebula Genomics continued that novel medicines would be built using Nebula’s database of anonymous genomic data to better understand the cause of diseases.

Nebula Genomics substantiated on the role of blockchain as –

“The success of research depends on successful recruitment and sustained engagement of patients. We believe that this requires a platform that puts the patient at the center by empowering and incentivizing them to become more actively engaged. To this end, we give our users tools to explore their genomic data, we use blockchain to let them control who can access it, and we ensure that they are compensated fairly for contributing to research. We hope that by doing so we can elevate the users of our platform from patients to partners, which will drive participation and benefit biomedical research.”

Nebula Genomics sustained by adding that this collaboration has significant capacity in accelerating scientific discovery and drug development for the benefit of patients. The genomics blockchain firm indicated that currently they were looking for lung cancer patients and offering a free high-coverage sequencing. Nebula genomics further added that they would give patients full access to their genomic data so that it can help make better treatment choices.

NEBULA GENOMICS INFORMED THAT THEY WERE STARTING A PILOT PROJECT, THE GOAL OF WHICH WAS TO HELP EMD SERONO TO EMBRACE ITS RESEARCH EFFORTS

Nebula Genomics expressed that when they launched Nebula Genomics last year, they had clarified their goal to make personal genome sequencing free. Nebula Genomics expressed that since then they had provided low-coverage sequencing to a multitude of people free of charge. In order to offer free service for more expensive sequencing, Nebula Genomics had established collaborations with pharma and biotech companies.

Similarly, Solve.Care, a global healthcare platform announced its partnership with pharmaceutical company Boehringer Ingelheim to launch a care network for patients with diabetes. Solve.Care headlined that the Diabetes Care Administration Network would provide patients and providers with information about diabetes. There would also be information shared about its associated risks using Solve.Care’s blockchain based platform.

Nebula Genomics wrapped up by throwing light on engaging patient communities. The blockchain genomics firm informed that since their inception last year, they had been growing their base by offering personal genomics services to consumers. This was in addition to engaging various patient communities and interest groups.